Ally Bridge Group

Activity from announced rounds

All recorded activity
Rounds participated in
4
Confirmed lead rounds
0
3 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$585M
4 disclosed · full round size, not this investor’s share

By stage

Series C+3
Growth1

By primary sector

Healthtech3
Biotech1

By country

United States3
Australia1

Rounds

4 in all activity
AdvanCell

AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.

$315MSeries D
Role not disclosed
Calyxo

Develops medical devices for kidney stone treatment and removal

$40MSeries F
Role not disclosed
Imperative Care

Develops treatments for patients suffering from thromboembolic disease

$100MGrowth
Role not disclosed